Glenn S. Van Aller

EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations

Michael T. McCabe, Heidi M. Ott, Gopinath Ganji et al. · Nature · 2012 · 1.8K citations

Ezh2 Inhibition, Lymphoid Neoplasia, Hematological Malignancy +10

EZH2 Is Required for Germinal Center Formation and Somatic EZH2 Mutations Promote Lymphoid Transformation

Wendy Béguelin, Relja Popovic, Matt Teater et al. · Cancer Cell · 2013 · 828 citations · Full text

Chromatin, Developmental Biology, Germ Cell +9

A DNA Hypomethylation Signature Predicts Antitumor Activity of LSD1 Inhibitors in SCLC

Helai P. Mohammad, Kimberly N. Smitheman, Chandrashekhar D. Kamat et al. · Cancer Cell · 2015 · 498 citations · Full text

Oncogenic Agent, Medicine, Epigenetic Change +9

SMYD3 links lysine methylation of MAP3K2 to Ras-driven cancer

Paweł K. Mazur, Nicolas Reynoird, Purvesh Khatri et al. · Nature · 2014 · 405 citations · Full text

Lysine Methylation, Medicine, Cancer Genomics +5

Identification of Potent, Selective, Cell-Active Inhibitors of the Histone Lysine Methyltransferase EZH2

Sharad K. Verma, Xinrong Tian, Louis V. LaFrance et al. · ACS Medicinal Chemistry Letters · 2012 · 373 citations · Full text

Histone Modifications, Drug Discovery Program, Engineering +18